NCT01073319

Rivastigmine as a Treatment for Methamphetamine Dependence

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Baylor College of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

To study the effects of treatment with rivastigmine on craving produced by experimental administration of methamphetamine.

Detailed description

We recently completed a double-blind placebo-controlled human laboratory study demonstrating that treatment with a low dose of the acetylcholinesterase (AChE) inhibitor rivastigmine reduced methamphetamine (METH)-induced craving (see Preliminary Studies, Fig. 2). This finding is consistent with the preclinical report indicating that the AChE inhibitor donepezil reduced METH-seeking behavior in rats following exposure to a non-contingent dose of METH (Hiranita et al. 2006). To extend our clinical findings, we propose a 3-year human laboratory study to evaluate effects of higher doses of rivastigmine on METH-induced craving and on self-administration of METH. Our recently completed work indicates that 3mg rivastigmine attenuated METH-induced craving in the laboratory. Given that higher dosages of this produce greater inhibition of nicotinic acetylcholine (ACh) receptors (in the treatment of Alzheimer's disease), it is reasonable to predict that 6mg and 12mg will have more pronounced effects on craving and other measures of reinforcement. This human laboratory study is a critical next step in the evaluation of rivastigmine as a potential treatment for METH dependence. We propose to include only participants exhibiting METH-induced craving by screening potential participants prior to admission (criterion based upon Preliminary Studies, Fig. 5). Selection of participants demonstrating METH-induced craving will facilitate assessment of effects of rivastigmine on craving. The project has the following objectives: Primary Objective: To characterize the effects of treatment with rivastigmine (0, 3, and 6 mg) on craving produced by experimental administration of METH (0, 15 and 30mg, IV). Secondary Objective: To characterize the effects of treatment with rivastigmine (0, 3, and 6 mg) on choices for METH exhibited in a self-administration paradigm (0 and 5mg, IV).

Conditions

• Methamphetamine Dependence
• Substance Abuse
• Methamphetamine Abuse

Interventions

Type	Name	Description
OTHER	Placebo	Administration of placebo pill
DRUG	Rivastigmine	Participants will be randomized to rivastigmine (1.5 mg bid) for 6 days of each phase.
DRUG	Rivastigmine	Participants will be randomized to rivastigmine (3 mg bid) for 6 days of each phase.

Timeline

• Start date: 2009-07-01
• Primary completion: 2010-07-01
• Completion: 2010-07-01
• First posted: 2010-02-23
• Last updated: 2012-07-27

Locations

1 site across 1 country: United States